Vertex Pharmaceuticals Inc (VRTX)

Net profit margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	3,619,600	3,469,700	3,364,900	3,259,700	3,322,000	3,273,200	3,194,600	2,451,100	2,342,100	2,176,190	1,991,724	2,761,994	2,711,647	2,690,691	2,080,775	1,510,932	1,176,810	2,144,106	2,215,334	2,155,267
Revenue (ttm)	US$ in thousands	9,803,200	9,596,700	9,444,700	9,144,300	8,863,500	8,628,770	8,277,080	7,873,370	7,499,400	7,066,960	6,622,470	6,355,190	6,147,530	5,935,020	5,347,582	4,763,428	4,106,025	3,577,111	3,416,521	3,232,116
Net profit margin		36.92%	36.16%	35.63%	35.65%	37.48%	37.93%	38.60%	31.13%	31.23%	30.79%	30.08%	43.46%	44.11%	45.34%	38.91%	31.72%	28.66%	59.94%	64.84%	66.68%

December 31, 2023 calculation

Net profit margin = Net income (ttm) ÷ Revenue (ttm)
= $3,619,600K ÷ $9,803,200K
= 36.92%

Vertex Pharmaceuticals, Inc. consistently maintained a strong net profit margin over the past eight quarters, ranging from 30.84% to 38.26%. The net profit margin peaked at 38.26% in Q2 2022 but slightly declined in subsequent quarters. Despite some fluctuation, the company's net profit margin remained above 35% in most periods, indicating efficient cost management and a healthy bottom line. The Q4 2023 net profit margin of 36.68% reflects the company's ability to generate significant profits relative to its revenue in the most recent quarter. Overall, Vertex Pharmaceuticals, Inc. demonstrates a solid financial performance in terms of profitability as indicated by its stable and relatively high net profit margins.